These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23935270)

  • 1. A comparison of the effects of losartan and ramipril on blood pressure, renal volume and progression in polycystic kidney disease: A 5-Year follow-up.
    Ulusoy S; Ozkan G; Kosucu P; Kaynar K; Eyuboglu I
    Hippokratia; 2012 Apr; 16(2):143-8. PubMed ID: 23935270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.
    Ulusoy S; Ozkan G; Orem C; Kaynar K; Koşucu P; Kiriş A
    Ren Fail; 2010; 32(8):913-7. PubMed ID: 20722556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.
    Scaglione R; Argano C; Corrao S; Di Chiara T; Licata A; Licata G
    J Hypertens; 2005 Mar; 23(3):657-64. PubMed ID: 15716710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.
    Spinar J; Vítovec J; Soucek M; Dusek L; Pavlík T;
    Vnitr Lek; 2009 May; 55(5):481-8. PubMed ID: 19514614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.
    Stallone G; Infante B; Grandaliano G; Bristogiannis C; Macarini L; Mezzopane D; Bruno F; Montemurno E; Schirinzi A; Sabbatini M; Pisani A; Tataranni T; Schena FP; Gesualdo L
    Nephrol Dial Transplant; 2012 Sep; 27(9):3560-7. PubMed ID: 22785114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].
    Xu R; Zhang Y; Zhang M; Li XC; Cai H; Chen WQ; Zhu H; Ge ZM; Zhang W
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(45):3199-204. PubMed ID: 16405840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial].
    Chazova IE; Martyniuk TV
    Ter Arkh; 2013; 85(10):10-22. PubMed ID: 24437213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of single and combined application of ramipril and losartan on renal structure and function in hypertensive rats.
    Yun L; Xu X; Dai Y; Xu R; Li G; Yao Y; Li J; Zheng F
    Clin Exp Hypertens; 2018; 40(7):617-623. PubMed ID: 29256643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
    Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
    Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.
    Kahvecioglu S; Akdag I; Gullulu M; Arabul M; Ersoy A; Dilek K; Yavuz M; Yurtkuran M
    Ren Fail; 2007; 29(2):169-75. PubMed ID: 17365932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of hypervolemia on electrolyte level and and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease].
    Michalski A; Grzeszczak W
    Pol Arch Med Wewn; 1996 Oct; 96(4):329-43. PubMed ID: 9082344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension.
    Cachofeiro V; Maeso R; Rodrigo E; Navarro J; Ruilope LM; Lahera V
    Hypertension; 1995 Aug; 26(2):236-43. PubMed ID: 7635531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).
    Joshi SR; Yeolekar ME; Tripathi KK; Giri J; Maity AK; Chopda M; Gujarathi S; Maroli S; Maity A;
    J Assoc Physicians India; 2004 Mar; 52():189-95. PubMed ID: 15636307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease.
    Ecder T; Chapman AB; Brosnahan GM; Edelstein CL; Johnson AM; Schrier RW
    Am J Kidney Dis; 2000 Mar; 35(3):427-32. PubMed ID: 10692268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients.
    Derosa G; Maffioli P; Ferrari I; Palumbo I; Randazzo S; Fogari E; D'Angelo A; Cicero AF
    Hypertens Res; 2011 Jan; 34(1):145-51. PubMed ID: 21107327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease.
    Choukroun G; Itakura Y; Albouze G; Christophe JL; Man NK; Grünfeld JP; Jungers P
    J Am Soc Nephrol; 1995 Dec; 6(6):1634-42. PubMed ID: 8749691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary Angiotensinogen in addition to Imaging Classification in the Prediction of Renal Outcome in Autosomal Dominant Polycystic Kidney Disease.
    Park HC; Kim J; Cho A; Kim DH; Lee YK; Ryu H; Kim H; Oh KH; Oh YK; Hwang YH; Lee KB; Kim SW; Kim YH; Lee J; Ahn C;
    J Korean Med Sci; 2020 Jun; 35(22):e165. PubMed ID: 32508065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction.
    Jover B; Hérizi A; Mimran A
    Hypertension; 1996 Jan; 27(1):79-84. PubMed ID: 8591893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
    Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
    BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.